FDA Webview
X

Free FDA Notices

Two Preemption Cases Back to District Courts

05/05/2009

The Third Circuit Court of Appeals has sent two drug preemption cases back to district courts for further proceedings in light of the Supreme Court’s ruling in Wyeth v. Levine. Colacicco v. Apotex was sent back to a Pennsylvania federal court, while McNellis v. Pfizer goes back to a New Jersey federal court. A three-judge appeals court panel noted that the Supreme Court had reversed the appeals court’s decision in the two cases and remanded for reconsideration in light of Wyeth v. Levine, in which the high court rejected the company’s contention that a state failure-to-warn suit was preempted by federal law.

The appeals court judges said they asked parties in the two cases to comment on the effect of the Wyeth decision on these two cases. The two drug companies said they believed that the appeals court ruling was consistent with Wyeth, while the plaintiff families said that the companies had not met the heavy burden imposed by the high court in Wyeth on manufacturers seeking to preempt failure-to-warn claims. The plaintiffs’ attorneys suggested that the appeals court reverse the preemption ruling in Colacicco and remand both cases to the district courts for further proceedings, and the appeals court agreed.

In a related action, the U.S. Solicitor General informed the appeals court that it was withdrawing its amicus brief filed in Colacicco in support of Apotex. “FDA has not yet conducted the sort of reexamination of various preemption issues following the Supreme Court’s decision in Wyeth that would be necessary to inform a position of the United States in this case,” the department said in a
letter to the court. “Accordingly, the United States hereby withdraws the amicus brief previously filed in this court.”

LATEST NEWS